HuGE Literature Finder
Records 1-4
UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan.
Annals of hematology 2015 Jan 94 (1): 65-9. Yamasaki Satoshi, Tanimoto Kazuki, Kohno Kentarou, Kadowaki Masanori, Takase Ken, Kondo Seiji, Kubota Akira, Takeshita Morishige, Okamura Seiic |
Pharmacogenetic analysis in the treatment of Hodgkin lymphoma.
Leukemia & lymphoma 2013 Aug 54 (8): 1706-12. Altés Albert, Paré Laia, Esquirol Albert, Xicoy Blanca, Rámila Elena, Vicente Laura, López Rosario, Orriols Jaume, Vall-llovera Ferran, Sánchez-González Blanca, del Río Elisabeth, Sureda Anna, Páez David, Baiget Montserr |
Polymorphisms in genes encoding interleukin-10 and drug metabolizing enzymes GSTP1, GSTT1, GSTA1 and UGT1A1 influence risk and outcome in Hodgkin lymphoma.
Leukemia & lymphoma 2012 Oct 53 (10): 1934-44. Yri Olav E, Ekstrøm Per O, Hilden Vera, Gaudernack Gustav, Liestøl Knut, Smeland Erlend B, Holte Hara |
Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis.
Blood 2009 Apr 113 (14): 3307-13. Ribrag Vincent, Koscielny Serge, Casasnovas Olivier, Cazeneuve Cecile, Brice Pauline, Morschhauser Franck, Gabarre Jean, Stamatoullas Aspasia, Lenoir Gilbert, Salles Gilles, |
- Page last reviewed:Oct 1, 2020
- Page last updated:Mar 03, 2021
- Content source: